The possibility of an increased risk of suicidality with psilocybin use is a serious outcome measure that requires further study

There are also reports on more severe effects, namely persistent psychosis and myocardial infarction.

Ill-conceived hallucinogen experimentation may induce unstable affect and even precipitate psychotic breaks

Despite psilocybin's apparent effectiveness in depression, people with bipolar have been excluded from all modern trials

Emotional volatility (including anxiety, depression and hypomania) were reported in the days and weeks following a psychedelic experience

Of the respondents, 2.6% behaved in a physically aggressive or violent manner and 2.7% received medical help

Outcomes were generally favorable, but negative effects appeared more frequent than in clinical settings

AEs are poorly defined in the context of psychedelic treatments and are probably underreported in the literature due to study design